Amarin achieves positive cash flow in Q4 2025 ahead of schedule; FY revenue $212-217M

AMARIN CORP PLCUK

2025-FY EPS reported -$0.09 revenue$213,646,000

Year-end cash $303M, up $16M from Q3; no debt; Q4 positive cash flow achieved earlier than forecast.
Q4 2025 net revenue expected $48-53M; FY 2025 net revenue $212-217M.
Restructuring: 50% of $70M OPEX savings realized; full benefit on track by June 30, 2026. Estimated restructuring costs raised to $37-40M.
VASCEPA >50% IPE prescription share in US; Recordati now managing European commercialization in most launched countries.
Two new regulatory approvals (South Korea and Singapore); >10 abstracts and >20 manuscripts published in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.